Results 21 to 30 of about 921,567 (386)

Diabetes and kidney cancer: A direct or indirect association? [PDF]

open access: yes, 2010
A positive association between diabetes and kidney cancer has been reported in several investigations, but it is unclear whether diabetes or its complications account for this association.
Bahij S. Nuwayhid   +4 more
core   +2 more sources

PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response

open access: yesJournal for ImmunoTherapy of Cancer, 2019
Background Programmed death-ligand 1 (PD-L1) expression in metastatic renal cell carcinoma (RCC) correlates with a worse prognosis, but whether it also predicts responsiveness to anti-PD-1/PD-L1 therapy remains unclear.
Joseph Vento   +13 more
doaj   +1 more source

Point of care parenchymal volume analyses to estimate split renal function and predict functional outcomes after radical nephrectomy

open access: yesScientific Reports, 2023
Accurate prediction of new baseline GFR (NBGFR) after radical nephrectomy (RN) can inform clinical management and patient counseling whenever RN is a strong consideration.
Nityam Rathi   +19 more
doaj   +1 more source

Patients With Kidney Cancer [PDF]

open access: yes, 2012
To develop a preoperative prognostic model in order to predict recurrence-free survival in patients with nonmetastatic kidney cancer.A multi-institutional data base of 1889 patients who underwent surgical resection between 1987 and 2007 for kidney cancer
B. Soyupak   +9 more
core   +2 more sources

Structure of the human gonadotropin-releasing hormone receptor GnRH1R reveals an unusual ligand binding mode

open access: yesNature Communications, 2020
The human gonadotropin-releasing hormone receptor GnRH1R is a GPCR with an important role in the human reproductive system and of interest as a drug target.
Wei Yan   +11 more
doaj   +1 more source

Progress and Comment on Immunotherapy of Advanced Renal Cell Carcinoma

open access: yesZhongliu Fangzhi Yanjiu, 2020
Immunotherapy has made great progress in the treatment of advanced renal cell carcinoma (RCC), since nivolumab was approved for the second-line therapy of advanced RCC.
ZHOU Li, SHENG Xi'nan
doaj   +1 more source

Direct observation of tRNA-chaperoned folding of a dynamic mRNA ensemble

open access: yesNature Communications, 2023
T-box riboswitches are multi-domain noncoding RNAs that surveil individual amino acid availabilities in most Gram-positive bacteria. T-boxes directly bind specific tRNAs, query their aminoacylation status to detect starvation, and feedback control the ...
Krishna C. Suddala   +6 more
doaj   +1 more source

Acute kidney injury in critically ill cancer patients : an update [PDF]

open access: yes, 2016
Patients with cancer represent a growing group among actual ICU admissions (up to 20 %). Due to their increased susceptibility to infectious and noninfectious complications related to the underlying cancer itself or its treatment, these patients ...
Benoit, Dominique   +3 more
core   +2 more sources

The therapeutic aspects of the endocannabinoid system (ECS) for cancer and their development: from nature to laboratory [PDF]

open access: yes, 2016
The endocannabinoid system (ECS) is a group of neuromodulatory lipids and their receptors, which are widely distributed in mammalian tissues. ECS regulates various cardiovascular, nervous, and immune system functions inside cells.
Botta, Bruno   +5 more
core   +1 more source

Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers

open access: yesEuropean Urology Open Science, 2021
Second primary cancers (SPCs) are increasing due to improving survival in first primary cancers. Previous studies on SPCs in renal cell carcinoma (RCC) have focused on treatment and other risk factors, but data of RCC as an SPC are scarce.In this study, we want to elucidate the risk for any SPC after RCC, and in reverse order, for RCC as an SPC after ...
Zheng, Guoqiao   +6 more
openaire   +6 more sources

Home - About - Disclaimer - Privacy